Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants with Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Trial Identifier:	3475-042
Sponsor:	MSD
Start Date:	October 2014
Primary Completion Date:	September 2018
Study Completion Date:	September 2022
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Results Plain Language Summary

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.